Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $54.71.

A number of research firms have weighed in on COAG. JPMorgan Chase & Co. started coverage on shares of Hemab Therapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $70.00 price target on the stock. Jefferies Financial Group increased their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. HC Wainwright increased their price objective on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Weiss Ratings downgraded shares of Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 25th. Finally, Rodman & Renshaw initiated coverage on shares of Hemab Therapeutics in a research report on Monday, October 12th. They set a “buy” rating and a $56.00 target price on the stock.

Hemab Therapeutics Price Performance

Shares of NASDAQ:COAG opened at $34.40 on Monday. The firm has a market cap of $1.61 billion and a price-to-earnings ratio of -1.39. Hemab Therapeutics has a 1-year low of $23.00 and a 1-year high of $55.42. The stock’s 50 day moving average price is $39.01.

Hemab Therapeutics (NASDAQ:COAG) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). As a group, equities research analysts anticipate that Hemab Therapeutics will post -3.10 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new stake in Hemab Therapeutics during the second quarter valued at approximately $230,000. The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at approximately $688,000. Opaleye Management Inc. bought a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at approximately $1,750,000. State Street Corp bought a new stake in shares of Hemab Therapeutics in the 2nd quarter valued at approximately $2,825,000. Finally, Braidwell LP acquired a new position in shares of Hemab Therapeutics in the 2nd quarter worth approximately $5,877,000.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious bleeding disorders. The company’s research is aimed at addressing conditions in which patients experience inadequate clot formation or difficulty controlling bleeding, including rare inherited and acquired disorders.

Hemab’s lead investigational program, HMB-001, is being developed as a potential treatment for Glanzmann thrombasthenia, a rare inherited platelet disorder that can cause severe and recurring bleeding.